Publications by authors named "Ricardo D Parrondo"

Claim this Profile
R
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.
Beatrice M Razzo, Shonali Midha, Andrew J Portuguese, Ariel F Grajales-Cruz, Andre De Menezes Silva Corraes, Ricardo D Parrondo

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy.
Melinda Sy Tan, Rahma Warsame, Ricardo D Parrondo, Eli Muchtar, Taxiarchis V Kourelis

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
Samuel Kosydar, William J Archibald, Paul J Hampel, Timothy G Call, Sara J Achenbach, Ricardo D Parrondo

Br J Haematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation.
Madhavi Nayyar, Ricardo C B de Menezes, Sikander Ailawadhi, Ricardo D Parrondo

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Ricardo D Parrondo

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience.
Ricardo D Parrondo, Saurav Das, Hanna Sledge, Leif Bergsagel, Rafael Fonseca

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Ricardo D Parrondo, Betsy R LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J Flott

Blood Cancer J· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Ricardo D Parrondo, Navnita Dutta, Betsy R LaPlant, Jamie Elliott, Andre Fernandez

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Ricardo D Parrondo, Sikander Ailawadhi, Claudio Cerchione

Front Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Ricardo D Parrondo, Madiha Iqbal, Reinhard Von Roemeling, Christina Von Roemeling, Han W Tun

Front Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience.
Farah Yassine, Mohamed A Kharfan-Dabaja, Athanasios Tsalantsanis, Vivek Roy, Abba C Zubair, Ricardo D Parrondo

Bone Marrow Transplant· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.
Saurav Das, Sikander Ailawadhi, Taimur Sher, Vivek Roy, Andre Fernandez, Ricardo D Parrondo

Curr Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers.
Sikander Ailawadhi, Meghna Ailawadhi, Navnita Dutta, Ricardo D Parrondo, Vivek Roy

Cancer Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.
Sikander Ailawadhi, Ricardo D Parrondo, Navnita Dutta, Bing Han, Gina Ciccio

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.
Sikander Ailawadhi, Ricardo D Parrondo, Muhamad Alhaj Moustafa, Betsy R LaPlant, Victoria Alegria

Hematol Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma.
Ricardo D Parrondo, Aneel Paulus, Sikander Ailawadhi

Cancers (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.
Ricardo D Parrondo, Zaid Abdel Rahman, Michael G Heckman, Mikolaj Wieczorek, Liuyan Jiang

Blood Cancer J· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.
Ricardo D Parrondo, Keren Sam, Ahsan Rasheed, Victoria Alegria, Taimur Sher

Blood Cancer J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plamotamab (XmAb13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia.
Ricardo D Parrondo, Aneel Paulus, Victoria Alegria, David Liebowitz, Chelsea Johnson

Leuk Lymphoma· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
Zaid H Abdel Rahman, Ricardo D Parrondo, Michael G Heckman, Mikolaj Wieczorek, Kevin C Miller

Br J Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelomatous ascites and pleural effusion in relapsed multiple myeloma.
Mizba Baksh, Ke Li, Liuyan Jiang, Victoria Alegria, Taimur Sher, Ricardo D Parrondo

Clin Case Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Oren Pasvolsky, Moshe Yeshurun, Raphael Fraser, Noel Estrada-Merly, Uri Rozovski, Ricardo D Parrondo

Bone Marrow Transplant· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.
Mizba Baksh, Liuyan Jiang, Unnati Bhatia, Victoria Alegria, Taimur Sher, Ricardo D Parrondo

Clin Case Rep· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia.
Ricardo D Parrondo, Muhamad Alhaj Moustafa, Craig Reeder, Taimur Sher, Vivek Roy

Clin Lymphoma Myeloma Leuk· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
Ricardo D Parrondo, Victoria Alegria, Vivek Roy, Taimur Sher, Asher A Chanan-Khan

Ann Hematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis